期刊
ONCOTARGETS AND THERAPY
卷 11, 期 -, 页码 8099-8106出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S181223
关键词
lipocalin 2; breast cancer; metastasis; triple-negative breast cancer; epithelial-to-mesenchymal transition; angiogenesis
资金
- Natural Science Foundation of China [81503301]
- Guangdong Medical Science Foundation [A2016511]
- Science and Technology Planning Project of Guangdong Province, China [2016A050503039]
Although systematic therapeutic approaches have reduced cancer-associated mortality, metastatic breast cancer can still evade therapy, particularly triple-negative breast cancer, which remains associated with high rates of cancer metastasis and has the worst clinical prognosis. Lipocalin 2 (LCN2) is a secreted glycoprotein that transports small lipophilic ligands. Its abnormal expression serves critical roles in the epithelial-to-mesenchymal transition process, angiogenesis, and cell migration and invasion in breast cancer. Notably, LCN2 functions as an initiator of carcinogenesis and metastasis by involving multiple signaling pathways. The present review aims to summarize research findings on the abnormal expression of LCN2 in breast cancer progression. Furthermore, the review highlights the latest developments of potential LCN2-targeting agents and proposed LCN2-associated molecular mechanisms with regard to breast cancer invasion and metastasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据